Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Content from other channels on our network

Testing beef trim sampling cloths for Escherichia coli O157:H7, STEC, and Salmonella species with harmonised enrichments

PhD opportunity in functional snack food innovation

Aseptic, minimal processing and flexible lines on show in 2027

Breaking the biofilm shield that harbours foodborne pathogens

Second cell-cultured food under assessment by FSANZ

Detoxifying 'super fungi' may recover critical minerals

Training centre opens to improve alloy lifecycle

Water utilities know where AI fits — but can the foundations carry it?

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Siemens announces AI-enabled software grant to UniSC

Deakin University launches metal resources research centre

Dragos introduces OT-native cybersecurity AI

Construction begins on south‍-‍west WA advanced manufacturing hub

Newcastle carbon capture plant opens